title: miR-10b is a prognostic marker in clear cell renal cell carcinoma.
abstract: OBJECTIVE
  Clear cell renal cell carcinoma (ccRCC) is the most common adult kidney cancer. It is an aggressive tumour with unpredictable outcome. The currently used clinical parameters are not always accurate for predicting disease behaviour. miR-10b is dysregulated in different malignancies including RCC.
  
  
  METHODS
  We assessed the clinical utility of miR-10b as a prognostic marker in 250 patients with primary ccRCC. We examined the correlation between miR-10b and clinicopathological parameters. We compared miR-10b expression among different RCC subtypes and normal kidney tissue.
  
  
  RESULTS
  We observed a stepwise decrease of miR-10b expression from normal kidney to primary ccRCC and a further decrease from primary to metastatic RCC. miR-10b expression was significantly lower in stages III/IV compared with stages I/II (p=0.038). Using a binary cut-off, miR-10b-positive patients had significantly longer disease-free survival (HR=0.47, CI 0.28 to 0.79, p=0.004). In the subgroup of patients with tumour size >4 cm, higher miR-10b expression was associated with significant longer disease-free and overall survival (p=0.001 and p=0.036, respectively). miR-10b was significantly downregulated in ccRCC compared with normal kidney (p<0.0001), and oncocytoma (p=0.031). It was also downregulated in chromophobe RCC. In addition, we identified a number of miR-10b-predicted targets and pathways that are involved in tumourigenesis.
  
  
  CONCLUSIONS
  Our data point to miR-10b as a promising prognostic marker in ccRCC with potential therapeutic applications.
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.|Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Heba W Z
authors.initials: HWZ
authors.lastname: Khella
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.
authors.forename: Nicole
authors.initials: N
authors.lastname: Daniel
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.
authors.forename: Leza
authors.initials: L
authors.lastname: Youssef
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece.
authors.forename: Andreas
authors.initials: A
authors.lastname: Scorilas
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.
authors.forename: Roy
authors.initials: R
authors.lastname: Nofech-Mozes
authors.affiliation: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Lorna
authors.initials: L
authors.lastname: Mirham
authors.affiliation: Department of Chemistry, Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario, Canada.
authors.forename: Sergey N
authors.initials: SN
authors.lastname: Krylov
authors.affiliation: Department of Chemistry, University of Athens, Athens, Greece.
authors.forename: Evi
authors.initials: E
authors.lastname: Liandeau
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.|Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Adriana
authors.initials: A
authors.lastname: Krizova
authors.affiliation: Division of Urologic Oncology, Department of Surgery, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Antonio
authors.initials: A
authors.lastname: Finelli
authors.affiliation: Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Cheng
authors.affiliation: Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.|Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: George M
authors.initials: GM
authors.lastname: Yousef
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D014408:Biomarkers, Tumor; C547183:MIRN10 microRNA, human; D035683:MicroRNAs
keywords: KIDNEY; METASTASIS; PCR; RENAL CANCER; TUMOUR MARKERS